Amgen buying Onyx for $10.4 billion to be bigger player in cancer therapies
Amgen said it will buy Onyx Pharmaceuticals for $10.4 billion in cash, or $125 a share, in a deal that significantly builds the big biotech company’s cancer drug program.
Amgen said it will buy Onyx Pharmaceuticals for $10.4 billion in cash, or $125 a share, in a deal that significantly builds the big biotech company’s cancer drug program.